Research programme: oncolytic virus therapies - Transgene/Randox

Drug Profile

Research programme: oncolytic virus therapies - Transgene/Randox

Alternative Names: Anticancer virus therapies - Randox/Transgene; Anticancer virus therapies - Transgene/Randox; Oncolytic immunotherapies - Randox/Transgene; Oncolytic immunotherapies - Transgene/Randox; Oncolytic virotherapies - Randox/Transgene; Oncolytic virotherapies - Transgene/Randox

Latest Information Update: 13 Oct 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Randox; Transgene
  • Developer Transgene
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Solid tumours

Most Recent Events

  • 02 Oct 2017 Transgene and Randox enter into a collaboration agreement to develop oncolytic virotherapies for Solid tumors
  • 02 Oct 2017 Early research in Solid tumours in France (IV)
  • 02 Oct 2017 Early research in Solid tumours in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top